Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Comment by mercedesmanon Dec 21, 2023 8:08am
143 Views
Post# 35795321

RE:MBX Q4 Earnings

RE:MBX Q4 Earnings

Pretty much as I expected , with fiscal 2023 being the proverbial " kitchen sink of underwhelming sales" but also the "repositioning for future growth" year. 


Still shocking to see VTM go from $5M to zero! Is there no market or replenishment (ie  restocking of shelves for expired media) needed anywhere in Canada ?

2023 winds up with a $16.5 M top line with a reasonable target of $2M/ month or $24M annually going forward. Thats a potential  of 50% top line growth from here. Better forward Guidance will  likely be provided in January. $20 - $24M  for 2024?

The above does not include Kinlytic licensing Revenues which presumably are still 3-4 years out ( but which will be material and have yet (IMO) to be fully factored into the SP.

Short term milestone/ upfront payments for Kinlytic made in Q1 will also boosts revenues and margins for fiscal 2024. 

Good to have 2023 behind us finally. Onward and upward from here. 


MM 
 

 

<< Previous
Bullboard Posts
Next >>